7:03 PM
 | 
Feb 24, 2015
 |  BC Extra  |  Clinical News

CymaBay falls on Phase IIb gout data

CymaBay Therapeutics Inc. (NASDAQ:CBAY) fell $2.27 (19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate ( MBX-102) to treat gout.

While the trial met its primary endpoint -- with those receiving 800 mg of the oral uricosuric acid demonstrating a 46% reduction in gout flare rate vs. 300 mg of allopurinol after 12...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >